Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Primarily used to screen for prostate cancer, PSA tests measure the level of prostate-specific antigen in the blood. “The ...

Secondary outcome-measures on quality-of-life (QoL) and treatment satisfaction are reported. Methods Patients, aged <68 yrs, with adenocarcinoma of the prostate ... placebo after OLT were not ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once, 20 to 30 percent will show signs of recurrence after the five-year mark ...

Q2 2025 Earnings Call Transcript January 8, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.04, ...

Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...